Immunogenicity and plasmid delivery pathways of non-invasive Lactococcus lactis -vectored mucosal DNA vaccination
Infection and Immunity · 2026
DOI: 10.1128/iai.00460-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infection and Immunity, 2026. Verfasst von Sarana Kawashima und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Microbiology and Immunology, Gifu Pharmaceutical University, Gifu, Japan. Hauptthemen laut MEDLINE: Lactococcus lactis, Vaccines, DNA, Plasmids, Genetic Vectors. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Lactic Acid Bacteria Foundation.
Abstract (Originalsprache)
Mucosal DNA vaccination using a non-invasive Lactococcus lactis (LL) vector has been investigated. However, its immunogenicity and plasmid transfer mechanisms remain largely unknown. In this study, we investigated the intranasal delivery of LL carrying a mammalian enhanced green fluorescent protein (EGFP)-expressing plasmid and the cellular pathways underlying DNA transfer. Intranasally administered LL was primarily localized on the nasal epithelial surfaces, and a smaller fraction penetrated the subepithelial tissues. Intranasal administration of LL-carrying pLEC-EGFP plasmid induces antigen-specific serum IgG and mucosal IgA responses. In vitro co-culture analyses demonstrated that plasmid delivery and expression occurred in phagocytic cell lines but not in epithelial cell lines. This transfer was inhibited by compounds specific for phagocytosis, consistent with the observed time course of DNA transfer and localization of LL within Lamp-1 + phagolysosomes. In contrast, compounds for bactericidal mechanisms, including lysosomal acidification, reactive oxygen species, and reactive nitrogen species, did not affect DNA transfer. As our findings suggest that phagocytosis is the primary pathway for plasmid delivery by non-invasive LL vectors in cell culture assays, further studies to confirm these findings in animal models are warranted to develop new strategies for improved LL-based mucosal DNA vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Microbiology and Immunology, Gifu Pharmaceutical University, Gifu, Japan.
ORCID-Profile: Keita Takahashi, Juri Koizumi, Tetsuo Koshizuka
Förderung
- Japan Society for the Promotion of Science
- Lactic Acid Bacteria Foundation
Zitieren
APA
Kawashima, S., Takahashi, K., Yanagisawa, D., Irikura, C., Kondo, H., Inoue, N., Koizumi, J., & Koshizuka, T. (2026). Immunogenicity and plasmid delivery pathways of non-invasive Lactococcus lactis -vectored mucosal DNA vaccination. Infection and Immunity. https://doi.org/10.1128/iai.00460-25
Vancouver
Kawashima S, Takahashi K, Yanagisawa D, Irikura C, Kondo H, Inoue N, et al. Immunogenicity and plasmid delivery pathways of non-invasive Lactococcus lactis -vectored mucosal DNA vaccination. Infection and Immunity. 2026. doi:10.1128/iai.00460-25
BibTeX
@article{Kawashima2026,
author = {Kawashima, Sarana and Takahashi, Keita and Yanagisawa, Daiki and Irikura, Chitose and Kondo, Hiroki and Inoue, Naoki and Koizumi, Juri and Koshizuka, Tetsuo},
title = {Immunogenicity and plasmid delivery pathways of non-invasive Lactococcus lactis -vectored mucosal DNA vaccination},
journal = {Infection and Immunity},
year = {2026},
doi = {10.1128/iai.00460-25}
}
EUVIMED